Haitong Securities Co (HK:6837) has released an update.
Haitong Innovation, a subsidiary of Haitong Securities Co, has entered into three partnership agreements to establish the IC, Biopharmaceutical, and AI Master Funds, all of which will function as private equity funds without being consolidated into the parent company’s financials. These agreements involve substantial capital commitments from various partners including Guosheng Group and Shanghai Guojing Investment, with Shanghai SCI Pioneer Private Equity Fund managing the funds. Due to the connections between the involved parties, these transactions fall under specific reporting and announcement regulations.
For further insights into HK:6837 stock, check out TipRanks’ Stock Analysis page.
